About this trial
The research objective is to compare the effects of infant formula supplemented with milk oligosaccharides and optimized with multiple nutrients on the immune function of infants under 1 year old with conventional infant formula, and to compare the effects of different infant formulas on infant intestinal health, immune function, growth and development, cognitive development, and tolerance with those of breastfed infants.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
0-28 days after birth;
Single birth;
The gestational age is between 37 and 42 weeks;
Birth weight ranges from 2500 to 4000 grams;
Disqualifiers
Artificial assisted reproduction;
The mother suffers from a disease that may endanger intrauterine growth;
The mother suffers from pregnancy diabetes or serious metabolic disease or chronic disease during pregnancy
Suffering from congenital malformations and genetic diseases, chronic diseases, and congenital diseases that may interfere with the investigation;
Trial design
Parallel
Treatments tested in this trial
oligosaccharides and multiple nutrients
Dietary supplementThe effect of adding milk oligosaccharides and optimizing multiple nutrients to infant formula on the growth and development of infants aged 0-1 years
no oligosaccharides and optimizing multiple nutrients
Dietary supplementThe effect of traditional infant formula milk powder optimized without adding milk oligosaccharides and multiple nutrients on the growth and development of infants aged 0-1 years old.
breastfeeding
Dietary supplementThe impact of breastfeeding on the growth and development of infants aged 0-1 years old.
Treatment groups
Trial outcomes
Primary outcomes
Intestinal indicators
16s rRNA
Intestinal indicators
SCFAs
Secondary outcomes
Inflammatory markers
serum hsCRP
Nutritional indicators
serum albumin
Immune indicators
fecal sIgA
Immune indicators
blood lymphocyte subsets
Other outcomes
adverse event
adverse event
Serious adverse events
Serious adverse events
Sponsors and contacts
Click on the lead sponsor to view all of their trials.